Thank you, Medsunman, for the update. Also, thanks to Bernie, via Henry.
It all appears to be very good news, yet the stock languishes. I have a suspicion that the market is telling us something about the prospective LLY drug that Ligand has the option to aquire. It is just a hunch on my part, but I think they might pass, after all. This would result in (1) an increase of 1.5% on the royalties for Ligand's retinoid-of-choice, and (2) an additional $20 million placement of LGND stock to LLY. My supposition is that it is the second point that is weighing on the stock (an over-reaction; the "dilution" involved is insubstantial, in my opinion.)
If this turns out to be the case, I, for one, will be thoroughly relieved (after getting over the shock of actually getting something right, for a change. ;-) The prospective drug that was discussed on the thread, some time ago, left me unimpressed, to say the least. Having said that, let me add that I trust the folks at Ligand to know their jobs a whole lot better than I do. And so, if they elect to take this LLY drug (or another one,) I will assume that it is the right call.
Does anyone know anything substantive, on this front?
RB |
